NTRK gene fusions have been identified in a diverse range of pediatric (notably infantile fibrosarcoma and high-grade glioma) and adult tumors, and in which TRK inhibitors can result in prolonged clinical response and improved patient outcomes4,17. This evidence concerns the gene NTRK1 and fibrosarcoma.